




### ReadyCell introduce HepatoReady™, fresh human hepatocytes Ready-to-use

Nowadays, the use of human *in vitro* hepatic models at early preclinical stages means that the process selecting drug candidates is becoming more rational. Culture human hepatocytes are considered up to date the gold standard model to anticipate *in vivo* metabolic pathways of drugs and new chemical entities. They represent an accepted *in vitro* model by the FDA for ADME-Tox studies.

HepatoReady™ kits contain 24 well plates with freshly-plated, high-viability and metabolically-active human hepatocytes.



### HepatoReady™ Features


- Phase I (CYP450 isoforms) and Phase II (UGT) drug-metabolizing enzyme activities
- Synthesis of plasma proteins (i.e., albumin,  $\alpha$ 1-antitrypsin)
- Carbohydrate metabolism (glucose release and glycogen formation)
- Bile acid, cholesterol and fatty acid synthesis
- Urea production

### HepatoReady™ Applications


- Metabolic stability
- Hepatic clearance
- Metabolic profiling
- Metabolite identification and structure elucidation
- Prediction of *in vivo* pharmacokinetics from *in vitro* data
- Drug-Drug interactions studies
- Drug toxicity associated with drug metabolism

### HepatoReady™ Benefits


- Suitable for induction experiments
- Suitable for short and long-term experiments
- User-friendly and easy-handling system
- Ready-to-use kit format
- Innovative Shipping-Medium
- Shipping medium easy to remove by liquefaction 37 °C



EU Arrival



USA Arrival



ROW Arrival



## Shipping medium

- ✓ Solid at room temperature ( liquid at 37°C )
- ✓ Preserves cell viability
- ✓ Permits differentiation process progression
- ✓ Do not affect cell culture properties
- ✓ Do not perturb monolayer integrity



## FOUR SIMPLE STEPS OF Hepatoready™

### RECEIVE

Ready-to-use cell barrier

### LIQUIFY


Liquefying of solid shipping medium at 37°C

### APPLY


Incubation with test compound

### ASSAY

Assessment of permeability /transport end point



HepatoReady™ CYP 450 (1A2, 2C9, 3A4, 2C19, 2E1, 2B6, 2D6 and 2A6) enzymatic activities on arrival at different worldwide locations.



Activities of main inducible human CYP450 enzymes after incubation with well-known inducers of CYP isoforms

